Vericiguat in heart failure with reduced ejection fraction: being confident in the face of uncertainty[引用] 维利西呱在射血分数降低型心力衰竭中的应用：面对不确定性保持信心
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
其他信息:
A Cannata, M Packer
European Heart Journal, 2025
academic.oup.com
… Vericiguat is an oral soluble guanylate cyclase activator which has been approved for selected patients with heart failure with reduced ejection fraction (HFrEF).Current use in clinical practice is based on the results of the VICTORIA trial, which studied patients with recent worsening heart failure and a high post-randomization event rate. In that trial, vericiguat exerted a small relative risk … Over 18.5 months of follow-up, vericiguat did not reduce the primary composite endpoint of cardiovascular death or heart failure hospitalization (HR 0.93 …
